Herein, we adopted the drug repurposing strategy and tested whether PF‐06409577 slowed renal cystogenesis through inhibition of both the mTOR pathway and CFTR function in cellular, ex vivo and in vivo models of ADPKD. This evidence concerns the gene MTOR and autosomal dominant polycystic kidney disease.